HTN, as monotherapy or in combination w/ thiazide diuretic, β-adrenoceptor blocking agent or ACE inhibitor. 1st-line treatment of myocardial ischemia due to fixed obstruction (stable angina) &/or vasospasm/vasoconstriction (Prinzmetal's or variant angina) of the coronary vasculature, as monotherapy or in combination w/ other anti-anginal drugs in patients w/ angina refractory to nitrates &/or adequate doses of β-blockers.
AdultHTN & angina Initially 5 mg once daily. Max: 10 mg. Childn & adolescent 6-17 yrHTN Initially 2.5 mg once daily, up-titrated to 5 mg once daily if BP goal is not achieved after 4 wk.
View Aforbes overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to dihydropyridine derivatives or amlodipine. Severe hypotension, shock (including cardiogenic shock), obstruction of the outflow tract of the left ventricle (eg, high grade aortic stenosis), hemodynamically unstable heart failure after acute MI.
Hypertensive crisis. CHF. Impaired hepatic & renal function. Amlodipine is not dialyzable. Severe hepatic impairment. Minor or moderate influence on the ability to drive & use machines. Amlodipine is excreted in human milk. Pregnancy & lactation. Childn <6 yr. Elderly.
C08CA01 - amlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Sign Out
